BIOM-14 Patterns, risk factors and management of CD19-directed Chimeric Antigen Receptor T-cell therapy failure in CNS lymphoma
CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) demonstrates encouraging activity in CNS lymphoma (CNSL), yet most patients ultimately develop progressive disease (PD). Predictors, radiographic patterns, and optimal salvage strategies after CD19-CAR failure remain poorly defined. We retrospectively...